Lv4
630 积分 2021-02-23 加入
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
4个月前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
5个月前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
5个月前
已完结
Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis
7个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
10个月前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
1年前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
1年前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
1年前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
1年前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
1年前
已完结
皖公网安备34019202002308
